China Approves Hengrui ANGPTL3 Antibody for HoFH

Company Jiangsu Hengrui Event Type NMPA approval (China) Modality Monoclonal antibody (subcutaneous) Asset Revocimab (SHR-1918) Target ANGPTL3 Disease Area Homozygous familial hypercholesterolemia Summary China approved Hengrui’s subcutaneous ANGPTL3 antibody revocimab (SHR-1918) for LDL-cholesterol lowering in adults and adolescents aged at least 12 with homozygous familial…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *